Publication of Peer-Reviewed Articles on VAL401

RNS Number : 9778X

ValiRx PLC

28 February 2017

 

ValiRx Plc

('ValiRx' or the 'Company')

PEER-REVIEWED PUBLISHED ARTICLES SUPPORTING VALIRX & VALISEEK'S ANTI-CANCER TECHNOLOGY

London, UK, 28 February 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces the recent publication of two articles in peer-reviewed journals that examine drug reprofiling in oncology and the progress of novel cancer treatment drug, VAL401, in its Clinical Efficacy trials for the treatment of lung cancer and other oncology indications.

Publications

The first article is titled "A Chemical Genomics Approach to Drug Reprofiling in Oncology: Antipsychotic Drug Risperidone as a Potential Adenocarcinoma Treatment". Accepted for publication in Cancer Letters, Volume 393, 2017, Pages 16-21 and co-authored by Dr Suzy Dilly, Professor Paul Taylor, University of Leeds, alongside other academic staff at both the University of Warwick and Leeds University, this peer-reviewed communication details the experimental processes that led to the formulation of the VAL401 process. 

The second publication is Bentham Science and is titled "Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling", Current Drug Discovery Technologies, 2017, 14, 000-000, by Dr George Morris, COO of ValiRx plc and Dr Suzy Dilly, CEO of ValiSeek.  They explore examples of success in reprofiling, draw comparisons between techniques, and finally provide two examples from the ValiRx plc development pipeline currently undergoing the process.

A third article appears as an advertising feature in the March 2017 issue of "BioPharma Dealmakers" (a Nature publication) describing the licensing opportunity of VAL401 as an oncology treatment and summarises the expectations of the current trial.

Future Conferences

Dr Victoria D'Aquino, Research and Development Officer at ValiRx, submitted an abstract on the current VAL201 clinical trial, which has been accepted for poster presentation at the 15^th International Congress on Targeted Anti-Cancer Therapies ("TAT") in Paris, France, on 6-8 March 2017.

Dr Suzy Dilly will attend the Bio-Europe Spring bio-partnering conference on 20-22 March 2017, in Barcelona, Spain.  This conference represents a further opportunity to continue to develop conversations with potential partners and licensees.

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

About ValiSeek

ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: [phone]
Tarquin Edwards, Head of Communications.	Tel: [phone] [e-mail]
Mark Treharne, Corporate Development Manager	Tel: [phone] [e-mail]

*** ENDS ***

 

END

 

 

NRADMGZZVNMGNZM